1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | LNCaP-Clone-FGC; LNCaP.FGC; LNCaP-FGC; LNCaP FGC; LNCAPCLONEFGC |
| Species | Human |
| Cat.No | ABC-TC0599 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Prostate Cancer Cell Lines |
The LNCaP cell line was established in 1977 from a metastatic lesion in the left supraclavicular lymph node of a 50-year-old Caucasian male with confirmed prostate carcinoma. These cells can grow either in aggregates or as single cells. LNCaP cells possess a high affinity for androgen receptors and respond to hormonal stimulation. They exhibit aneuploid chromosome numbers ranging from 76 to 91 and express Prostate Specific Antigen (PSA). Unlike other cell lines, LNCaP cells do not form a uniform monolayer but grow in clusters that need to be dissociated through pipetting during subculture. They have a weak attachment to the substrate, do not reach confluence, and rapidly acidify the growth medium. As a result, their growth is very slow.
Why choose LNCaP from AcceGen?
The LNCaP cell from AcceGen offers several key features. It is provided sterile and has been tested to be negative for bacteria, fungi, and mycoplasma, 
ensuring a clean and reliable culture. The cells undergo professional incubation and cryopreservation processes, guaranteeing high viability upon receipt. Additionally, the product is backed by professional and standardized operations, along with rigorous quality control measures, ensuring consistent and reliable performance for experimental and research purposes.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
The LNCaP cell line, derived from human prostate cells, finds application in the development of the CDX (Cell Line Derived Xenograft) LNCaP xenograft mouse model. This model is particularly valuable for studying androgen sensitivity, as LNCaP cells possess a mutated androgen receptor (AR T877A). The LNCaP xenograft model serves as an androgen-dependent system and is utilized for evaluating various treatment modalities targeting the androgen receptor, such as androgen receptor antisense oligonucleotides or bicalutamide. This model provides a platform to investigate the efficacy and mechanisms of action of these interventions in the context of androgen-dependent prostate cancer.
